Role of red blood cells in thrombosis

Current Opinion in Hematology

Volumn 6, Issue 2, 1999, Pages 76-82

  Andrews, Dina A ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR;

BLOOD CLOTTING; ENDOTHELIUM CELL; ERYTHROCYTE; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS;

BLOOD VISCOSITY; DISEASE SUSCEPTIBILITY; ERYTHROCYTE COUNT; ERYTHROCYTES; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 0032811978     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199903000-00004     Document Type: Review

References (131)

1. Duke WW: The relation of blood platelets to hemorrhagic disease. JAMA 1910, 55:1185-1192.
2. Hellem AJ, Borchgrevink CF, Ames SB: The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961, 7:42-50.
3. Ho CH: The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia. Transfusion 1996, 36:290.
4. Blajchman MA, Bordin JO, Bardossy L, Heddle NM: The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol 1994, 86:347-350.
5. Ho CH: Increase of red blood cells can shorten the bleeding time in patients with iron deficiency anemia. Blood 1998, 91:1094.
6. Livio M, Marchesi D, Remuzzi G, Gotti E, Mecca G, deGaetano G: Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982, 2:1013-1015.
7. Zwaginga JJ, Ijsseldijk MJW, de Groot PG, Kooistra M, Vos J, van Es A, et al.: Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 1991, 66:638-647.
8. Weiss HJ, Lages B, Hoffmann T, Turitto VT: Correction of the platelet adhesion defect in δ-storage pool deficiency at elevated hematocrit-possible role of adensoine diphosphate. Blood 1996, 87:4214-4222.
9. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984, 64:1-12.
10. Randi ML, Stocco F, Rossi C, Tison T, Girolami A: Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 1991, 22:213-223.
11. Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A: Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 1998, 244:49-53.
12. Wehmeier A, Daum I, Jamin H, Schneider W: Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients. Ann Hematol 1991, 63:101-106.
13. Boneu B: Laboratory investigations and prediction of thrombotic risk in polycythemia vera. Nouv Rev Fr Hematol 1994, 36:183-185.
14. Carallo C, Pujia A, Irace C, Defranceschi MS, Motti C, Gnasso A: Whole blood viscosity and haematocrit are associated with internal carotid atherosclerosis in men. Coron Artery Dis 1998, 9:113-117.
15. Harrison MJG, Pollock S, Kendall BE, Marshall J: Effect of haematocrit on carotid stenosis and cerebral infarction. Lancet 1981, 2:114-115.
16. Stewart GW, Amess JAL, Eber SW, Kingswood C, Lane PA, Smith BD, Mentzer WC: Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996, 93:303-310.
17. Smith BD, Segel GB: Abnormal erythrocyte endothelial adherence in hereditary stomatocytosis. Blood 1997, 89:3451-3456.
18. Michaeli JM, Mittelman M, Grisaru D, Rachmilewitz EA: Thromboembolic complications in beta thalassemia major. Acta Hematol 1992, 87:71-74.
19. Wong V, Yu YL, Liang RHS, Tso WK, Li AMC, Chan TK: Cerebral thrombosis in β-thalassemia. Stroke 1990, 21:812-816.
20. Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, Rachmilewitz E, Yedgar S: Enhanced aggregability of red blood cells of β-thalassemia major patients. Am J Physiol 1996, 270:H1951-H1956.
21. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A: Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost 1996, 76:322-327.
22. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, et al.: In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 1997, 98:51-56.
23. Koshy M, Thomas C, Goodwin T: Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys 1990, 1:71-78.
24. Wick TM, Eckman JR: Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 1996, 3:118-124.
25. Kaysser TM, Wandersee NJ, Bronson RT, Barker JE: Thrombosis and secondary hemochromatosis play major roles in the pathogenesis of jaundiced and spherocytic mice, murine models for hereditary spherocytosis. Blood 1997, 90:4610-4619. Ja/ja and spherocytic mice, both with well-characterized RBC membrane defects, have thrombi on postmortem examination.
26. Southgate CD, Chishti AH, Mitchell B, Yi SJ, Palek J: Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Nat Genet 1996, 14:227-230.
27. Hassoun H, Wang Y, Vassiliadis J, Lutchman M, Pale J, Aish L, et al.: Targeted inactivation of murine band 3 (AE1) gene produces a hypercoagulable state causing widespread thrombosis in vivo. Blood 1998, 92:1785-1792. A hypercoagulable state leading to death in band 3 null neonatal mice is attributed to abnormal PS exposure on the outer leaflet of the RBC membrane.
28. Liu SC, Palek J, Yi SJ, Nichols PE, Derick LH, Chiou SS, et al.: Molecular basis of altered red blood cell membrane properties in Southeast Asian ovalocytosis: role of the mutant band 3 protein in band 3 oligomerization and retention by the membrane skeleton. Blood 1995, 86:349-359.
29. Mohandas N, Lie-Injo LE, Friedman M, Mak JW: Rigid membranes of Malayan ovalocytes: a likely genetic barrier against malaria. Blood 1984, 63:1385-1392.
30. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC, et al.: Risk factors for hemiretinal vein occlusion - comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998, 105:765-771.
31. Lip PL, Blann AD, Jones AF, Lip GYH: Abnormalities in haemorheological factors and lipoprotein (A) in retinal vascular occlusion-implications for increased vascular risk. Eye 1998, 12:245-251.
32. El-Asrar AM, Al-Momen A, Al-Amro S, Gader A, Tabbara KF: Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996, 20:197-204.
33. Trope GE, Lowe GDO, McArdle BM: Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983, 67:137-142.
34. Peduzzi M, Codeluppi L, Poggi M, Baraldi P: Abnormal blood viscosity and erythrocyte deformability in retinal vein occlusion. Am J Ophthalmol 1983, 96:399-400.
35. Chabanel A, Glacet-Bernard A, Lelong F, Taccoen A, Coscas G, Samama MM: Increased red blood cell aggregation in retinal vein occlusion. Br J Haematol 1990, 75:127-131.
36. Zannad F, Stoltz J-F: Blood rheology in arterial hypertension. J Hypertens 1992, 10:S69-S78.
37. Martinez M, Vaya A, Labios M, Gabriel F, Guiral V, Aznar J: The effect of long-term treatment with hypotensive drugs on blood viscosity and erythrocyte deformability in patients with essential arterial hypertension. Clin Hemorheol Microcirc 1997, 17:193-198.
38. Zioupos P, Barbenel JC, Lowe GDO, Macrury S: Foot microcirculation and blood rheology in diabetes. J Biomed Eng 1993, 15:155-158.
39. Stoltz JF, Donner M: New trends in clinical hemorheology: an introduction to the concept of the hemorheological profile. Schweiz Med Wochenschr 1991, 121:41-49.
40. Zimmermann J, Schramm L, Wanner C, Mulzer E, Henrich HA, Langer R, Heidbreder E: Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy. Clin Nephrol 1996, 46:230-236.
41. Hayakawa M, Kuzuya F: Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders. Angiology 1991, 42:747-753.
42. Chabanel A, Horellou MH, Conard J, Samama MM: Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment. Br J Haematol 1994, 88:174-179.
43. Dermiroglu H: The importance of erythrocyte aggregation in blood rheology: considerations on the pathophysiology of thrombotic disorders. Blood 1997, 89:4236.
44. Kwaan HC, Levin M, Sakurai S, Kucuk O, Rooney MW, Lis LJ, Kauffman JW: Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia. J Vasc Surg 1997, 26:1061-1068.
45. Dawicki DD, Agarwal KC, Parks RE Jr: Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985, 34:3965-3972.
46. Kolassa N, Plank B, Turnheim K: pH and temperature dependence of adenosine uptake in human erythrocytes. Eur J Pharmacol 1978, 52:345-351.
47. Moser GH, Schrader J, Deussen A: Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989, 256:C799-C806.
48. Gresele P, Arnout J, Deckmyn H, Vermylen J: Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986, 55:12-18.
49. Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD: Effect of dipyridamole on spontaneous platelet aggregation in whole blood decreases with the time after venepuncture: evidence for the role of ADP. Thromb Haemost 1987, 58:744-748.
50. Yeung PKF, Mosher SJ, Li R, Farmer PS, Klassen GA, Pollak PT, et al.: Erythrocyte adenosine transport: a rapid screening test for cardiovascular drugs. J Pharmacol Toxicol Methods 1993, 30:163-167.
51. De La Cruz JP, Maximo MA, Blanco E, Moreno A, Sanchez de la Cuesta F: Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro. Thromb Res 1997, 86:515-524.
52. Kronen G, Ferder M, Hunzicker K, Strauch B: The use of pentoxifylline in microvascular surgery. J Reconstr Microsurg 1994, 10:17-20.
53. Solerte SB, Fioravanti M, Cerutti N, Severgnini S, Locatelli M, Pezza N, et al.: Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol 1997, 34:67-74.
54. Martinez M, Vaya A, Llopis I, Carbonell P, Gilsanz A, Aznar J: Pentoxifylline and erythrocyte deformability. Thromb Res 1994, 74:551-552.
55. Schmid-Schonbein H, Wells R, Goldstone J: Influence of deformability of human red cell upon blood viscosity. Circ Res 1969, 25:131-143.
56. Goldsmith HL: Red cell motions and wall interactions in tube flow. Fed Proc 1971, 30:1578-1588.
57. Goldsmith HL, Bell DN, Braovac S, Steinberg A, McIntosh F: Physical and chemical effects of red cells in the shear-induced aggregation of human platelets. Biophys J 1995, 69:1584-1595.
58. Aarts PAMM, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ: Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood 1983, 62:214-217.
59. Eckstein EC, Belgacem F: Model of platelet transport in flowing blood with drift and diffusion terms. Biophys J 1991, 60:53-69.
60. James SH, Meyers AM: Microangiopathic hemolytic anemia as a complication of diabetes mellitus. Am J Med Sci 1998, 315:211-215.
61. Hebbel RP: Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991, 77:214-237.
62. Hellem AJ: The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960, 12(suppl):51.
63. Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD: Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985, 38:225-232.
64. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, et al.: Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991, 78:154-162.
65. Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, et al.: Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest 1991, 87:571-580.
66. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, et al.: Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998, 97:350-355.
67. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB: Prothrombotic effects of erythrocytes on platelet reactivity: reduction by aspirin. Circulation 1997, 95:63-68.
68. Santos MT, Valles J, Aznar J, Perez-Requejo JL: Role of red blood cells in the early stages of platelet activation by collagen. Thromb Haemost 1986, 56:376-381.
69. Perez-Requejo JL, Aznar J, Santos MT, Valles J: Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (basic wave). Thromb Haemost 1985, 54:799-803.
70. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA: Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961, 192:531-532.
71. Reimers RC, Sutera SP, Joist JH: Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood 1984, 64:1200-1206.
72. Born GVR, Wehmeier A: Inhibition of platelet thrombus formation by chlorpromazine acting to diminish haemolysis. Nature 1979, 282:212-213.
73. Born GVR: Evidence for inhibition of platelet activation in blood by a drug effect on erythrocytes. Nature 1976, 259:233-235.
74. ++-concentration. Br J Haematol 1981, 47:149-152.
75. Born GVR: Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation 1985, 72:741-746.
76. Ellsworth ML, Gaarder A, Duke WW: The erythrocyte as a regulator of vascular tone. Am J Physiol 1995, 38:H2155-H2161.
77. Bergfeld GR, Forrester T: Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 1992, 26:40-47.
78. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ: ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol 1996, 271:H2717-H2722.
79. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al.: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561. This article summarizes a number of RBC adhesion receptors.
80. Wautier J-L, Wautier M-P, Schmidt A-M, Anderson GM, Hori O, Zoukourian C, et al.: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994, 91:7742-7746.
81. Hebbel RP: Perspectives series: cell adhesion in vascular biology: adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997, 100:S83-S86.
82. Oh SS, Chishti AH, Palek J, Liu S-C: Erythrocyte membrane alterations in Plasmodium falciparum malaria sequestration. Curr Opin Hematol 1997, 4:148-154.
83. Coppel RL, Cooke BM, Magowan C, Mohandas N: Malaria and the erythrocyte. Curr Opin Hematol 1998, 5:132-138.
84. Treutiger CJ, Heddini A, Fernandez V, Muller WA, Wahlgren M: PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes. Nat Med 1997, 3:1405-1408.
85. Ho M, Schollaardt T, Niu X, Looareesuwan S, Patel KD, Kubes P: Characterization of Plasmodium falciparum-infected erythrocyte and P-selectin interaction under flow conditions. Blood 1998, 91:4803-4809.
86. Chen Q, Barragan A, Fernandez V, Sundstrom A, Schlichtherle M, Sahlen A, et al.: Identification of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) as the rosetting ligand of the malaria parasite P. falciparum. J Exp Med 1998, 187:15-23.
87. Serghides L, Crandall I, Hull E, Kain KC: The Plasmodium falciparum-CD36 interaction is modified by a single amino acid substitution in CD36. Blood 1998, 92:1814-1819.
88. Chu Y, Haigh T, Nash GB: Rheological analysis of the formation of rosettes by red blood cells parasitized by Plasmodium falciparum. Br J Haematol 1997, 99:777-783.
89. Crandall I, Sherman IW: The human anion transport protein, band 3, contains a CD36-like binding domain for Plasmodium falciparum-infected erythrocytes. Parasitology 1996, 112:261-267.
90. Lucas JZ, Sherman IW: Plasmodium falciparum: thrombospondin mediates parasitized erythrocyte band 3-related adhesin binding. Exp Parasitol 1998, 89:78-85.
91. McCormick CJ, Craig A, Roberts D, Newbold CI, Berendt AR: Intercellular adhesion molecule-1 and CD36 synergize to mediate adherence of Plasmodium falciparum-infected erythrocytes to cultured human microvascular endothelial cells. J Clin Invest 1997, 100:2521-2529.
92. Telen MJ, Udani M, Washington MK, Levesque MC, Lloyd E, Rao N: A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding. J Biol Chem 1996, 271:7147-7153.
93. Hale LP, Singer KH, Haynes BF: CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. J Immunol 1989, 143:3944-3948.
94. Bailly P, Hermand P, Callebaut I, Sonneborn HH, Khamlichi S, Mornon J-P, Cartron J-P: The LW blood group glycoprotein is homologous to intercellular adhesion molecules. Proc Natl Acad Sci U S A 1994, 91:5306-5310.
95. Lindberg FP, Lublin DM, Telen MJ, Veile RA, Miller YE, Donis-Keller H, Brown EJ: Rh-related antigen CD47 is the signal-transducer integrin-associated protein. J Biol Chem 1994, 269:1567-1570.
96. Gao A-G, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA: Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996, 271:21-24.
97. Udani M, Zen Q, Cottman M, Leonard N, Jefferson S, Daymont C, et al.: Basal cell adhesion molecule/Lutheran protein: the receptor critical for sickle cell adhesion to laminin. J Clin Invest 1998, 101:2550-2558.
98. El Nemer W, Gane P, Colin Y, Bony V, Rahuel C, Galacteros F, et al.: The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules. J Biol Chem 1998, 273:16686-16693.
99. Hillery CA, Du MC, Montgomery RR, Scott JP: Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood 1996, 87:4879-4886.
100. van Schravendijk MR, Handunnetti SM, Barnwell JW, Howard RJ: Normal human erythrocytes express CD36, an adhesion molecule of monocytes, platelets, and endothelial cells. Blood 1992, 80:2105-2114.
101. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993, 82:3548-3555.
102. Sugihara K, Sugihara T, Mohandas N, Hebbel RP: Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells, Blood 1992, 80:2634-2642.
103. 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993, 82:1891-1899.
104. Thevenin BJM, Crandall I, Ballas SK, Sherman IW, Shohet SB: Band 3 peptides block the adherence of sickle cells to endothelial cells in vitro. Blood 1997, 90:4172-4179.
105. Tilley L, Foley M, Anders RF, Dluzewski AR, Gratzer WB, Jones GL, Sawyer WH: Rotational dynamics of the integral membrane protein, band 3, as a probe of the membrane events associated with Plasmodium falciparum infections of human erythrocytes. Biochim Biophys Acta 1990, 1025:135-142.
106. Winograd E, Greenan JR, Sherman IW: Expression of senescent antigen on erythrocytes infected with a knobby variant of the human malaria parasite Plasmodium falciparum. Proc Natl Acad Sci U S A 1987, 84:1931-1935.
107. Winograd E, Sherman IW: Characterization of a modified red cell membrane protein expressed on erythrocytes infected with the human malaria parasite Plasmodium falciparum: possible role as a cytoadherent mediating protein. J Cell Biol 1989, 108:23-30.
108. Bernstein E, Kairinen E: Scanning electron micrograph of erythrocyte enmeshed in a fibrin network. Science 1971, 173:765.
109. 1 integrin receptors on sickle reticulocytes and fibronectin. Blood 1996, 88:4348-4358.
110. Natarajan M, Udden MM, McIntire LV: Adhesion of sickle red blood cells and damage to interleukin-1β stimulated endothelial cells under flow in vitro. Blood 1996, 87:4845-4852.
111. Smolinski PA, Offermann MK, Eckman JR, Wick TM: Double-stranded RNA induces sickle erythrocyte adherence to endothelium: a potential role for viral infection in vaso-occlusion pain episodes in sickle cell anemia. Blood 1995, 85:2945-2950.
112. Setty BNY, Chen DC, Oneal P, Littrell JB, Grossman MH, Stuart MJ: Eicosanoids in sickle cell disease-potential relevance of 12(S)-Hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion. J Lab Clin Med 1998, 131:344-353.
113. Yamaja Setty BN, Dampier CD, Stuart MJ: Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium. J Lab Clin Med 1995, 125:608-617.
114. Kasschau MR, Barabino GA, Bridges KR, Golan DE: Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996, 87:771-780.
115. Fadlon E, Vordermeier S, Pearson TC, Miresluis AR, Dumonde DC, Phillips J, et al.: Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998, 91:266-274.
116. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F: Platelet activation in patients with sickle cell disease. Br J Haematol 1998, 100:741-749.
117. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993, 81:2137-2143.
118. Kawakami S, Kaibara M, Kawamoto Y, Yamanaka K: Rheological approach to the analysis of blood coagulation in endothelial cell-coated tubes: activation of the intrinsic reaction on the erythrocyte surface. Biorheology 1995, 32:521-536.
119. Zwaal RFA, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132. This article discusses the role of phospholipid flip-flop in hemostasis.
120. Zhou Q, Zhao J, Stout JG, Luhm RA, Wiedmer T, Sims PJ: Molecular cloning of human plasma membrane phospholipid scramblase: a protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem 1997, 272:18240-18244.
121. + channel in human erythrocytes and alters cell volume and filterability. J Biol Chem 1996, 271:18651-18656.
122. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996, 88:1873-1880.
123. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD, Lubin BH: Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood 1996, 87:1179-1187.
124. Tait JF, Gibson DF: Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994, 123:741-748.
125. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, et al.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997, 276:2034-2037.
126. Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996, 380:221-226.
127. Pawloski JR, Swaminathan RV, Stamler JS: Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggreagation. Circulation 1998, 97:263-267.
128. Sprague RS, Stephenson AH, Dimmit RA, Weintraub NA, Branch CA, McMurdo L, Lonigro AJ: Effect of L-NAME on pressure-flow relationships in isolated rabbit lungs: role of red blood cells. Am J Physiol 1997, 269:H1941-H1948.
129. ++] elevation induced by erythrocyte components in endothelial cells. J Pharmacol Exp Ther 1996, 277:1501-1509.
130. Luthje J, Schomburg A, Ogilvie A: Demonstration of a novel ecto-enzyme on human erythrocytes, capable of degrading ADP and of inhibiting ADP-induced platelet aggregation. Eur J Biochem 1988, 175:285-289.
131. Minetti G, Low PS: Erythrocyte signal transduction pathways and their possible functions. Curr Opin Hematol 1997, 4:116-121.